Harvard Heart Letter

FDA withdraws approval for two older cholesterol drugs

Research we’re watching In April, the FDA took the unusual move of withdrawing its approval for drugs that contain niacin or fenofibric acid when used in combination with a statin for lowering high cholesterol. The ruling affects four medications: extended-release niacin (Niaspan), extended-release niacin combined with lovastatin (Advicor) or simvastatin (Simcor), and fenofibric acid (Trilipix), as well as their generic counterparts. …

To continue reading this article you must be registered.

Get Licensed Content to Harvard Health

If you are interested in licensing content from Harvard Health Publications, please contact us using our online form. Our licensing and business development professionals will help you leverage consumer health content from Harvard Medical School as a clear differentiator in helping achieve your business goals.

Contact Us

Customer Log In